[Role of antiaggregant platelet drugs in thromboembolism].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D003911:Dextrans / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D006801:Humans; D008943:Mitral Valve / Q000473:pathology; D010974:Platelet Aggregation / Q000187:drug effects*; D010979:Platelet Function Tests; D011725:Pyridines / Q000627:therapeutic use; D011727:Pyridinolcarbamate / Q000627:therapeutic use; D011897:Random Allocation; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013468:Suloctidil / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy*; D013988:Ticlopidine
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000900:Anti-Bacterial Agents; D003911:Dextrans; D011725:Pyridines; D013876:Thiophenes; D004176:Dipyridamole; D011727:Pyridinolcarbamate; D013988:Ticlopidine; D001241:Aspirin; D013442:Sulfinpyrazone; D013468:Suloctidil
Ruolo dei farmaci antiaggreganti piastrinici nelle malattie trombo-emboliche.